Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

FDA Approves Ziprasidone for Adjunctive Maintenance Treatment of Bipolar Disorder NEW YORK -- November 20, 2009 -- The US Food and Drug Administration (FDA) has approved ziprasidone HCI (Geodon) tablets for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The efficacy and safety of ziprasidone HCI for the adjunctive maintenance treatment of bipolar disorder were studied in a 6-month, double-blind, randomised, placebo-controlled trial in adult patients with bipolar I disorder. After an open-label stabilisation period of 10 to 16 weeks, 240 patients were randomised to continue on ziprasidone HCI plus lithium or valproate, or to have ziprasidone HCI replaced by placebo. The primary endpoint was time to recurrence of a mood episode requiring intervention. The data demonstrated that ziprasidone HCI plus lithium or valproate was superior to placebo plus lithium or valproate in increasing the time to recurrence of a mood episode. During 6 months of treatment, 19.7% of patients in the ziprasidone HCI arm required intervention for a mood episode, compared with 32.4% of patients in the placebo arm. The adjunctive treatment regimen was generally well-tolerated. Discontinuation due to adverse events occurred in 13% of patients in the placebo group, compared with 9 % of those in the ziprasidone HCI group. The safety and tolerability data from this study are consistent with ziprasidone’s already well-established safety profile in adult patients. SOURCE: Pfizer E-mail this page to a friend or colleague! To print, use this version